English
Regional settings| Spread | 0.0510 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 3.5295 |
| Open | 3.5495 |
| 1-Year Change | -32.56% |
| Day's Range | 3.5495 - 3.6095 |
Harvard Bioscience, Inc. is a developer, manufacturer, and seller of technologies, products and services that enable fundamental research, discovery, and preclinical testing for drug development. The Company provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms, and clinical. The Company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The Company’s customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.
BRIEF: For the fiscal year ended 31 December 2021, Harvard Bioscience, Inc. revenues increased 16% to $118.9M. Net loss decreased 96% to $288K. Revenues reflect United States segment increase of 18% to $49.8M, Europe segment increase of 19% to $35.8M. Lower net loss reflects Interest expense decrease of 68% to $1.5M (expense), G/L on early Exting of lease relat debt decrease from $1.9M (expense) to $0K.
Common Stock $.01 Par, 12/10, 80M auth., 36,057,974 issd., less 7,745,507 shs. in Treas. @ 10.7M. Insiders & Strategic holders own 13.56%. IPO: 12/7/2000, 6,420,000 shs. @$8 by Thomas Weisel Partners LLC. *NOTE: 10/02, Company acquired Genomic Solutions, Inc. @ 0.1017 shares and $0.286 in cash (3,178,857 shares issd.).
